Research programme: heart failure therapeutics - Cytokinetics/AmgenAlternative Names: cardiac sacromere activators; CK 0689705; CK 1122534; CK 1213296; CK 1316719; CK 689705
Latest Information Update: 10 Jun 2015
At a glance
- Originator Cytokinetics
- Developer Amgen; Cytokinetics
- Class Small molecules
- Mechanism of Action Cardiac myosin stimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Heart failure